ADC Product DS Release Specific Testing

ADC product DS release-specific testing is a core quality attribute service for antibody‑drug conjugates. It systematically quantifies the drug‑to‑antibody ratio, free payload residual, and unconjugated antibody ratio in ADC drug substance, with methods aligned with ICH Q6B and global regulatory standards for biologics.

Antibody‑drug conjugates covalently link highly potent cytotoxic payloads to monoclonal antibodies via chemical linkers, combining the targeting specificity of antibodies with the potent killing ability of chemical drugs. Since the first ADC approval in 2000, more than 15 ADCs have been approved worldwide, targeting HER2, CD30, Trop‑2, and other antigens. The structural complexity and heterogeneity of ADCs pose unique CMC challenges: the conjugation reaction produces a mixture of ADC variants with different drug loads; unconjugated antibodies and free payload residuals may affect safety and efficacy.

Creative Biogene provides one‑stop services from ADC DS release testing to IND/BLA submission data packages, designed to align with ICH Q6B and industry best practices, including method development, validation, and transfer.

Technical Principles & Test Methods

An ADC consists of three parts: a monoclonal antibody, a linker, and a cytotoxic payload. The conjugation reaction produces a mixture of species with different drug loads, typically characterized by the average DAR (drug‑to‑antibody ratio). DAR directly affects ADC potency and safety window – too low a drug load results in insufficient efficacy, while too high a drug load may increase off‑target toxicity. ADC heterogeneity arises from differences in conjugation sites, drug load distribution, and residuals of free drug and unconjugated antibody.

For ADC product release, DAR, free payload residual, and unconjugated antibody ratio are critical quality attributes affecting safety and efficacy. Per ICH Q6B, specifications must be established based on identified CQAs, including numerical limits and analytical methods.

At a glance – ADC DS release test panel

DAR Detection

DAR is the core quality parameter for ADCs, defined as the average number of drug molecules conjugated per antibody. DAR directly affects ADC potency, pharmacokinetics, and therapeutic window – for cysteine‑linked ADCs, studies have shown that high DAR correlates with faster plasma clearance and increased hepatotoxicity. Precise DAR control is critical for batch‑to‑batch consistency.

Method 1: HIC‑HPLC

Hydrophobic interaction chromatography utilizes the increased hydrophobicity of antibodies after drug conjugation, eluting DAR variants under different salt gradient conditions. For cysteine‑linked ADCs, DAR 0 (unconjugated antibody) has the lowest hydrophobicity and elutes first; DAR 2, DAR 4, DAR 6, and DAR 8 variants elute sequentially with increasing hydrophobicity. For lysine‑linked ADCs, the DAR profile is more complex and HIC may resolve a distribution rather than discrete peaks. Average DAR and drug load distribution are calculated from peak areas of each variant.

Method 2: LC‑MS

Intact antibody LC‑MS directly determines DAR and drug load distribution. Subunit LC‑MS (analysis of light and heavy chains after reduction) provides conjugation site‑specific information. Native affinity LC‑MS can directly analyze DAR and drug load distribution in complex matrices without offline enrichment and extensive chromatographic separation.

Method 3: RP‑HPLC – Complementary Separation Method

Reversed‑phase chromatography separates DAR variants based on hydrophobicity changes from drug conjugation, typically using C4 or C8 columns under acidic elution conditions. Compared to HIC, RP‑HPLC offers higher resolution but may denature ADC structures; it is primarily used for complementary analysis and confirmation.

Free Payload Residual Detection

After the conjugation reaction, small amounts of free payload‑linker small molecules typically remain in the ADC preparation. These free drug small molecules can enter non‑target cells by passive diffusion, causing off‑target toxicity and narrowing the therapeutic window. FDA and ICH Q6B require quantitative control of process‑related impurities, and free payload must be strictly monitored as a critical process impurity.

Even after rigorous purification steps, trace free drug may still be present in the formulated ADC, potentially narrowing the therapeutic window. LC‑MS detection provides high specificity and sensitivity for evaluating trace free drug. Developing sensitive multi‑dimensional methods to detect trace free drug in ADC samples is key to ensuring product quality and safety.

Method 1: RP‑LC‑MS/MS

Free payload is separated by reversed‑phase liquid chromatography, and tandem mass spectrometry (MRM) provides high‑sensitivity and high‑specificity quantitation. Both free payload and its derivatives (e.g., N‑acetylcysteine adducts) can be detected simultaneously. LC‑MS/MS achieves femtogram‑level detection sensitivity, orders of magnitude higher than UV detection.

Method 2: RP‑HPLC‑UV

Free payload is separated by reversed‑phase liquid chromatography, and UV detection at the payload’s characteristic absorption wavelength (e.g., 210‑350 nm) provides quantitation. Suitable for routine monitoring when free payload concentration is relatively high.

Unconjugated Antibody Ratio Detection

Unconjugated antibody (DAR 0) is the antibody variant in the ADC sample that is not conjugated to any drug molecule. DAR 0 lacks cytotoxic effect, binds to target antigens without delivering drug, and competes with conjugated ADC for target sites, reducing effective drug delivery efficiency. A high proportion of unconjugated antibody requires higher doses to achieve the same efficacy, increasing treatment cost and non‑specific exposure risk. DAR 0 is a critical impurity for ADC product quality control.

Method 1: HIC‑HPLC Direct Quantitation

HIC‑HPLC not only determines average DAR but also directly quantifies the unconjugated antibody ratio by the DAR 0 peak area. The DAR 0 peak area percentage is the proportion of unconjugated antibody relative to total antibody.

Method 2: RP‑HPLC

Reversed‑phase chromatography can also separate DAR 0 variants and may provide better resolution for certain ADC types.

Note – Complete testing scope

In addition to the ADC-specific assays described below, our drug substance release testing includes all universal release tests required by ICH Q6B (sterility, endotoxin, subvisible particulates, pH, osmolality, protein concentration, HCP/HCD residuals, etc.). For a full test matrix, please refer to our Drug Substance Release Testing Service page.

Regulatory Basis

Advantages

• Full coverage of three core quality attributes: DAR, free payload residual, and unconjugated antibody ratio – complete data for DS release to IND/BLA submission.
• HIC‑HPLC as primary DAR release method – optimized hydrophobic interaction chromatography effectively resolves DAR variants (0–8 for cysteine‑linked ADCs); high resolution ensures accurate quantitation of average DAR and drug load distribution.
• High‑sensitivity free payload LC‑MS/MS platform – triple quadrupole MS with MRM detection achieves LLOQ down to 10 nM (370 pg on‑column), approximately two orders of magnitude more sensitive than UV detection, meeting trace free payload release testing requirements.
• LC‑MS structural confirmation capability – multi‑level MS analysis at intact protein, subunit, and peptide levels supports DAR confirmation, conjugation site identification, and drug‑related modification characterization.
• ICH Q6B full validation – all methods validated per ICH Q2(R1)/Q2(R2) covering specificity, precision, accuracy, linearity, range, and robustness.
• Broad ADC product coverage – cysteine‑linked ADCs, lysine‑linked ADCs, site‑specific ADCs, and other ADC formats.
• State‑of‑the‑art methodologies – offering native SEC‑MS and native affinity LC‑MS for deep characterization.

Contact Us

For a customized DS release testing strategy, method validation, or IND/BLA submission support for your ADC product, contact Creative Biogene’s technical team.

FAQ